ClinicalTrials.gg
Active, not recruitingNCT05250973AQUARIUSUpdated Nov 3, 2026

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

A Phase 2 interventional study of Daratumumab and Cyclophosphamide in Amyloidosis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Updated Nov 3, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Enrollment
28th of 99
151 · median 45
Started
2022
with 4 others
Phase 2
30 of 141
5 open now
Primary completion
2026-02
later than 3 of 46 live
Registered
100th of 141
by date
Lead sponsor
3 of 141
Janssen Research & Development, LLC

Among the 141 studies in Amyloidosis with a site in United States, this one is the 28th largest by enrollment of the 99 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 in phase 2, reaches primary completion later than 3 of the 46 other live ones, and was the 100th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).

03

Conditions studied

  • Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: Cardiac involvement (amyloid light chain [AL] amyloidosis Mayo Cardiac Stage II and Stage IIIa) with or without other organ(s) involved; Cohort 2: One or more organs impacted by systemic AL amyloidosis according to consensus guidelines
  • (ECOG) Performance Status score of 0, 1 or 2
  • A female participant of must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
  • A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 6 months after receiving the last dose of cyclophosphamide or 100 days after discontinuation of daratumumab, whichever is longer
  • Cohort 2 only: self-identified racial and ethnic minorities, including Black or African American
  • at screening defined by one of the following:

Difference between iFLC and uninvolved FLC (dFLC) >= 40mg/L per central laboratory Serum involved free light chain (iFLC) >= 40 mg/L with an abnormal kappa:lambda ratio Serum M-protein >= 0.5 g/dL

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for systemic AL amyloidosis or multiple myeloma including medications that target cluster of differentiation 38 (CD38), with the exception of 160 milligrams(mg) dexamethasone or equivalent maximum exposure prior to randomization/enrollment
  • Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60% plasma cells in the bone marrow, or hypercalcemia related to myeloma.
  • Participant received any of the following therapies:

    1. treatment with an drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is less;
    2. vaccinated with an investigational vaccine (except for COVID-19) live, attenuated or replicating viral vector vaccines less than (\<) 4 weeks prior to randomization/enrollment. Participants who are taking strong Cytochrome P450 3A4() inducers must discontinue their use at least 5 half-lives prior to the first dose of bortezomib
  • Stem cell transplantation -Planned stem cell transplant during the first 9 cycles of protocol therapy are excluded. Stem cell collection during the first 9 cycles of protocol therapy is permitted
  • Grade 2 sensory or Grade 1 painful peripheral neuropathy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Cohort1 (Arm A): Daratumumab + Immediate Cyclophosphamide, Bortezomib and Dexamethasone (VCd)

    Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).

    Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Cohort1 (Arm B): Daratumumab + Deferred VCd

    Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m\^2 either orally or IV, Bortezomib 1.3 mg/m\^2 SC or IV, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).

    Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Cohort 2: Daratumumab + VCd

    Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).

    Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Daratumumab will be administered subcutaneously.

    Also known as: JNJ-54767414

  • Cyclophosphamide will be administered either orally or IV.

  • Bortezomib will be administered by SC injection or IV.

  • Dexamethasone will be administered orally or IV.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Cardiac Events of Any Toxicity Grade

    Number of participants with cardiac events of any toxicity grade will be reported.

    Time frame: Up to 12 months

  2. Observed Concentration Immediately Prior to the Next Study Treatment Administration (Ctrough) of Daratumumab

    Ctrough is defined as the observed concentration immediately prior to the next study treatment administration.

    Time frame: Cycle 3 Day 1 predose (each cycle is of 28 days)

Secondary outcomes

  1. Overall Complete Hematologic Response (HemCR) Rate

    Overall HemCR rate is defined as percentage of participants who achieve HemCR during or after the study treatment.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  2. HemCR Rate

    HemCR rate at 6 month is defined as percentage of participants who achieve HemCR at 6 month during or after the study treatment.

    Time frame: At 6 months

  3. Very Good Partial Response (VGPR) or Better Rate

    Hematologic greater than or equal to (\>=) VGPR rate is defined as percentage of participants who achieve hematologic response of VGPR or better.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  4. Time to HemCR or (VGPR or Better)

    For participants who achieve HemCR (or \>=VGPR), time to HemCR (or \>=VGPR) is defined as the time between the date of first study treatment and the first efficacy evaluation at which the participant has met all criteria for hematologic complete response (CR) (or \>=VGPR).

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  5. Duration of Response (HemCR and VGPR or Better)

    For participants who achieve HemCR (or \>=VGPR), duration of HemCR (or \>=VGPR) is defined as the time between the date of initial documentation of HemCR (or \>=VGPR) to the date of first documented evidence of hematologic progressive disease or death, whichever comes first.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  6. Organ Response Rate (OrRR)

    Organ response rate is defined as the percentage of participants who achieve organ response in each corresponding organ (kidney, heart, liver).

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  7. Overall Survival (OS)

    OS is measured from the date of first study treatment to the date of the participant's death.

    Time frame: Until Cycle 12 or Month 12 (whichever occurs later)

  8. Time to Subsequent Therapy

    Time to subsequent therapy for amyloid light chain (AL) amyloidosis is defined as the time from the date of first study treatment to the start date of subsequent AL amyloidosis (non-protocol) treatment.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  9. Number of Participants with Adverse Events (AEs) by Severity

    Number of participants with AEs by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  10. Serum Concentration of Daratumumab

    Serum samples will be analyzed to determine concentrations of daratumumab.

    Time frame: Up to 3 years

  11. Number of Participants with Antibodies to Daratumumab

    Number of participants with antibodies to daratumumab will be reported.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  12. Number of Participants with Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)

    Number of participants with antibodies to rHuPH20 will be reported.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

  13. Change from Baseline in Clinical Signs and Symptoms Score of Cardiac AL Amyloidosis

    Change from baseline in clinical signs and symptoms score of cardiac AL amyloidosis will be reported.

    Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

07

Study locations

46 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Feb 2026, 47 months.

Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's 47 months is close to that.

Completion moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Feb 22, 2022
StartActual
Mar 1, 2022
Primary completionActual
Feb 4, 2026
CompletionEst.
Nov 12, 2026was Oct 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Oct 26, 2026→Nov 12, 2026
moved 2 times, Sep 25, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Study completion Nov 23, 2026→Nov 12, 2026
    + 2 other changes: verification date and site details
  2. Sep 25, 2026
    Study completion Oct 26, 2026→Nov 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05250973
Responsible party
Sponsor
First posted
Feb 22, 2022
Start date
Mar 1, 2022
Primary completion
Feb 4, 2026
Completion
Nov 12, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion